Drugs in search of diseases

Science Translational Medicine

Volumn 5, Issue 186, 2013, Pages

  Paul, Steven M ^a,b   Lewis Hall, Freda ^c  

^a FEIL FAMILY BRAIN AND MIND RESEARCH INSTITUTE   (United States)

^b THIRD ROCK VENTURES   (United States)

^c PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

SILDENAFIL; THALIDOMIDE;

DRUG APPROVAL; DRUG INDICATION; DRUG INDUSTRY; DRUG RESEARCH; ERECTILE DYSFUNCTION; FUNDING; HUMAN; LEPROSY; MULTIPLE MYELOMA; NEGLECTED DISEASE; OFF LABEL DRUG USE; PATENT; PRIORITY JOURNAL; PUBLIC-PRIVATE PARTNERSHIP; PULMONARY HYPERTENSION; SHORT SURVEY;

COOPERATIVE BEHAVIOR; DISEASE; DRUG INDUSTRY; DRUG REPOSITIONING; HUMANS; PHARMACEUTICAL PREPARATIONS; PILOT PROJECTS;

EID: 84878338493     PISSN: 19466234     EISSN: 19466242     Source Type: Journal    
DOI: 10.1126/scitranslmed.3004452     Document Type: Short Survey

References (10)

1. S. M. Paul, D. S. Mytelka, C. T. Dunwiddie, C. C. Persinger, B. H. Munos, S. R. Lindborg, A. L. Schacht, How to improve R&D productivity: The pharmaceutical industry's grand challenge. Nat. Rev. Drug Discov. 9, 203-214 (2010).
2. T. T. Ashburn, K. B. Thor, Drug repositioning: Identifying and developing new uses for existing drugs. Nat. Rev. Drug Discov. 3, 673-683 (2004).
3. H. A. Ghofrani, I. H. Osterloh, F. Grimminger, Sildenafil: From angina to erectile dysfunction to pulmonary hypertension and beyond. Nat. Rev. Drug Discov. 5, 689-702 (2006).
4. N. Kumar, U. Sharma, C. Singh, B. Singh, Thalidomide: Chemistry, therapeutic potential and oxidative stress induced teratogenicity. Curr. Top. Med. Chem. 12, 1436-1455 (2012).
5. National Center for Advancing Translational Sciences, U.S. Department of Health and Human Services, National Instistutes of Health, Discovering new therapeutic uses for existing molecules; available at www.ncats.nih.gov/ research/reengineering/rescue-repurpose/therapeutic-uses/therapeutic-uses.html.
6. The NCATS industry collaborators are Pfizer, AstraZeneca, Eli Lilly, AbbVie, Bristol-Myers Squibb, GlaxoSmith-Kline, Johnson & Johnson, and Sanofi.
7. Medical Research Council, MRC/AstraZeneca: Mechanisms of Disease call for proposals; available at www.mrc.ac.uk/Fundingopportunities/Calls/MoD/ MRC008389#content.
8. J. Arrowsmith, Trial watch: Phase II failures: 2008-2010. Nat. Rev. Drug Discov. 10, 328-329 (2011).
9. J. Arrowsmith, Trial watch: Phase III and submission failures: 2007-2010. Nat. Rev. Drug Discov. 10, 87 (2011).
10. C. Clift, in ipHandbook of Best Practices, A. Krattiger, Ed. (Concept Foundation, Geneva, Switzerland, 2012) pp. 431-435.